Facebook-f Twitter Linkedin Youtube
SUBSCRIBE
Facebook-f Twitter Linkedin Youtube

Hematology / Oncology CE Activities

Hematology / oncology blog

View Details

Targeting BCMA: A New Path in Relapsed/Refractory Multiple Myeloma

In triple- and quad-refractory myeloma, median survival was only about 9 months, and less than 6 months in penta-refractory disease.
  • Hematology / Oncology
  • Blog
DOWNLOAD
View Details

Navigating Immunotherapy in Advanced NSCLC: What Every Oncologist Should Know

The advent of immunotherapy has significantly extended survival and revolutionized care in advanced non-small cell lung cancer (NSCLC).
  • Hematology / Oncology
  • Blog
DOWNLOAD
View Details

Is Immunotherapy Right for Your Patient with Nonmelanoma Skin Cancer?

The primary goal of treatment in nonmelanoma skin cancer (NMSC) is tumor elimination with maximal preservation of function and cosmesis.
  • Hematology / Oncology
  • Blog
DOWNLOAD

RMEI Presentations

RMEI DECISION SUPPORT AIDS

View Details

Intravitreal Anti-VEGF & Bispecific Therapies for DME & nAMD

In late 2022, the ocular implant, insertion tool assembly, (including the drug vial & initial fill needle) for ranibizumab PDS were voluntarily recalled due to septum dislodgement and paused implantations including ongoing global clinical trials; this did not include the refill vial and needle.
  • Hematology / Oncology
  • Decision Support Aid
DOWNLOAD
View Details

Cervical Cancer: What You Need to Know About Screening, Symptoms, and Treatments

This Decision Support Aid serves as a quick reference to help clinicians to apply information to their daily practice and care of patients. An estimated 13,960 women are diagnosed with invasive cervical cancer every year.
  • Hematology / Oncology
  • Decision Support Aid
DOWNLOAD
View Details

Seeing Nonmelanoma Skin Cancers Through A New Lens: The Role and Place of Immunotherapy

This Decision Support Aid serves as a quick reference to help clinicians to apply information to their daily practice and care of patients.
  • Hematology / Oncology
  • Decision Support Aid
DOWNLOAD
View Details

Relapsed or Refractory Chronic-Phase: CHRONIC MYELOID LEUKEMIA (CML)

This Decision Support Aid serves as a quick reference to help clinicians to apply information to their daily practice and care of patients.
  • Hematology / Oncology
  • Decision Support Aid
DOWNLOAD

LATEST HEMATOLOGY / ONCOLOGY ARTICLES

RSS Latest Hematology / Oncology Articles
  • Specificity of CRISPR-Cas9 Editing in Exagamglogene Autotemcel May 9, 2024
    The autologous cellular therapy exagamglogene autotemcel is generated by editing an erythroid-specific enhancer of BCL11A. Could another site be edited unintentionally? This study gauged the likelihood of off-target editing.
    Angela Yen, Zachary Zappala, Rebecca S. Fine, Timothy D. Majarian, Parin Sripakdeevong, David Altshuler
  • Exagamglogene Autotemcel for Severe Sickle Cell Disease May 9, 2024
    Of 30 patients with severe sickle cell disease who were treated with gene-edited autologous hematopoietic stem and progenitor cells, 29 were free from vaso-occlusive crises for at least 12 consecutive months.
    Haydar Frangoul, Franco Locatelli, Akshay Sharma, Monica Bhatia, Markus Mapara, Lyndsay Molinari, Donna Wall, Robert I. Liem, Paul Telfer, Ami J. Shah, Marina Cavazzana, Selim Corbacioglu, Damiano Rondelli, Roland Meisel, Laurence Dedeken, Stephan Lobitz, Mariane de Montalembert, Martin H. Steinberg, Mark C. Walters, Michael J. Eckrich, Suzan Imren, Laura Bower, Christopher Simard, Weiyu Zhou, Fengjuan Xuan, Phuong Khanh Morrow, William E. Hobbs, Stephan A. Grupp, the CLIMB SCD-121 Study Group*
  • Welcoming the Era of Gene Editing in Medicine May 9, 2024
    Recent approvals of exa-cel for treatment of sickle cell disease and transfusion-dependent β-thalassemia mark the dawn of the era of gene editing in medicine. But ensuring access will be challenging.
    George Q. Daley

RMEI LIGHTNING TALKS

View Details

4 Years, 16 Live & Online Activities, 6000+ Clinicians: What we've learned so far

RMEI has released pairings of live and online programs approximately twice per year since 2016 grouped into “phases” which share clinical areas of focus and are based on findings from the previous phase of education. In total, 16 activities have launched to date with 4 activities currently live. The purpose of this analysis is to better understand the impact of multi-year iterative education on a clinical audience. Presented at: Society for Academic CME (SACME), virtual, February 2021; Accreditation Council for Continuing Medical Education (ACCME), virtual, April 2021.
  • Allergy & Immunology
  • 2021
View Details

Effectiveness of 5-year IBD Provider Online Educational Intervention Program

There is considerable practice variability among providers caring for inflammatory bowel disease (IBD) patients. Limited data exists on the effectiveness of educational interventions targeting IBD providers to address these gaps. We report outcomes for a 5-year provider education training program which culminated in an enduring online education resource and clinical decision support tool.
  • Gastroenterology
  • 2021

Previously Published CE Activities

Copyright © 2024. RMEI Medical Education, LLC. All rights reserved​

Privacy | Terms of Use